세계의 불활성화 인플루엔자 백신 시장 보고서(2025년)

Inactivated Influenza Vaccine Global Market Report 2025

US $ 4,490 ￦ 6,222,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,993,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,765,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

불활성화 인플루엔자 백신 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 8.5%의 성장률로 99억 9,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 4가 백신에 대한 수요 증가, 예방접종 프로그램 확대, 전염병 예방에 대한 관심 증가, 백신 제조 기술 발전, 백신에 대한 전 세계 접근성 증가 등에 기인하는 것으로 보입니다. 이 기간 동안 주요 동향으로는 세포 기반 백신 제조로의 전환, 보조제제제 채택 확대, 독감 백신과 코로나19 부스터의 통합, 신흥 시장에서 수요 증가, 개인 맞춤형 백신 전략 개발 등을 꼽을 수 있습니다.

정부의 백신 접종 프로그램의 성장으로 불활성화 인플루엔자 백신 시장이 크게 성장하고 있습니다. 공중보건에 대한 인식이 높아짐에 따라 각국 정부는 예방접종에 대한 노력을 강화하고 있으며, 이는 백신에 대한 수요 증가와 보다 편리한 예방접종 서비스 제공으로 이어지고 있습니다. 이러한 프로그램은 고위험군에게 비활성화 독감 백신을 무료 또는 보조금으로 제공하여 백신 접종을 널리 보급하고 독감의 계절적 부담을 줄이는 데 중요한 역할을 하고 있습니다. 예를 들어, 2023년 12월 영국 국민보건서비스(NHS)는 새로운 예방접종 전략을 도입하여, 특히 소외된 지역사회에 대한 예방접종 보급 활동을 개선하는 것을 목표로 하고 있습니다. 이 전략은 예방접종 접근성을 확대하고 공중 보건을 더욱 증진시키는 것을 목표로 하고 있으며, 비활성화 독감 백신 시장의 성장을 가속할 것으로 예측됩니다.

불활성화 인플루엔자 백신 시장의 주요 기업들은 4가 백신 개발에 점점 더 많은 노력을 기울이고 있습니다. 4가 백신은 4가지의 서로 다른 독감 바이러스 균주를 방어하도록 설계되어 보다 광범위한 방어력을 제공하고 백신의 효능을 향상시킵니다. 예를 들어, 2025년 2월 인도에 본사를 둔 제약회사 자이더스 생명과학(Zydus Lifesciences)는 4가 불활성화 인플루엔자 백신인 백시플루-4(VaxiFlu-4)를 출시하여 4가지 독감 바이러스 균주에 대한 예방 효과를 제공했습니다. 이 백신은 인플루엔자 A형과 B형을 모두 커버하여 백신 불일치 위험을 줄이고, 계절성 독감 유행에 대한 예방 효과를 높이며, 지역 역학 동향에 따라 면역반응을 조절합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 불활성화 인플루엔자 백신 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 불활성화 인플루엔자 백신 시장 : 성장률 분석
• 세계의 불활성화 인플루엔자 백신 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 불활성화 인플루엔자 백신 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계 불활성화 인플루엔자 백신 전체 시장(TAM)

제6장 시장 세분화

• 세계의 불활성화 인플루엔자 백신 시장 : 백신 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 3가 불활성화 인플루엔자 백신(TIIV)
• 4가 불활성화 인플루엔자 백신(QIIV)
• 세계의 불활성화 인플루엔자 백신 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 소아
• 청년기
• 성인
• 고령자
• 세계의 불활성화 인플루엔자 백신 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 온라인 약국
• 공중위생 클리닉
• 세계의 불활성화 인플루엔자 백신 시장 : 최종사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 의료 제공자
• 개인
• 정부기관
• 제약회사
• 세계의 불활성화 인플루엔자 백신 시장 : 3가 불활성화 인플루엔자 백신(TIIV), 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 계란 기반 3가 불활성화 인플루엔자 백신
• 세포 기반 3가 불활성화 인플루엔자 백신
• 항원보강제 첨가 3가 불활성화 인플루엔자 백신
• 고용량 3가 불활성화 인플루엔자 백신
• 세계의 불활성화 인플루엔자 백신 시장 : 4가 불활성화 인플루엔자 백신(QIIV), 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 계란 기반 4가 불활성화 인플루엔자 백신
• 세포 기반 4가 불활성화 인플루엔자 백신
• 항원보강제 첨가 4가 불활성화 인플루엔자 백신
• 재조합 4가 불활성화 인플루엔자 백신
• 소아 4가 불활성화 인플루엔자 백신

제7장 지역별/국가별 분석

• 세계의 불활성화 인플루엔자 백신 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 불활성화 인플루엔자 백신 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 불활성화 인플루엔자 백신 시장 : 경쟁 구도
• 불활성화 인플루엔자 백신 시장 : 기업 개요
  • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi S.A. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Abbott Laboratories
• Novartis International
• GlaxoSmithKline plc
• Viatris Inc.
• CSL
• Zydus Lifesciences Limited
• Sinovac Biotech Ltd.
• Bharat Biotech International Limited
• Dalian Aleph Biomedical Co. Ltd.
• Hualan Biological Bacterin Co. Ltd
• Changchun Biological
• Jiangsu gdk Biotechnology Co., Ltd.
• KM Biologics
• JoinHub Pharma
• Pharmika India Private Limited

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 불활성화 인플루엔자 백신 시장, 2029년 : 새로운 기회를 제공하는 국가
• 불활성화 인플루엔자 백신 시장, 2029년 : 새로운 기회를 제공하는 부문
• 불활성화 인플루엔자 백신 시장, 2029년 : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Inactivated influenza vaccines are flu vaccines that contain viruses that have been killed or inactivated. These vaccines stimulate the immune system to produce antibodies against the influenza virus and are administered via injection to help prevent seasonal influenza infections.

The main types of vaccines in the inactivated influenza vaccine market include the trivalent inactivated influenza vaccine (TIIV) and the quadrivalent inactivated influenza vaccine (QIIV). The trivalent inactivated influenza vaccine contains three inactivated virus strains two influenza A strains and one influenza B strain to provide protection against seasonal influenza. These vaccines are used across various age groups, including children, adolescents, adults, and the elderly, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and public health clinics. End users include healthcare providers, individuals, government organizations, and pharmaceutical companies.

The inactivated influenza vaccine market research report is one of a series of new reports from The Business Research Company that provides inactivated influenza vaccine market statistics, including inactivated influenza vaccine industry global market size, regional shares, competitors with an inactivated influenza vaccine market share, detailed inactivated influenza vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the inactivated influenza vaccine industry. This inactivated influenza vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inactivated influenza vaccine market size has grown strongly in recent years. It will grow from$6.62 billion in 2024 to $7.21 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth during the historic period can be attributed to increased seasonal influenza outbreaks, government vaccination campaigns, a rising elderly population, improved public health awareness, and the expansion of healthcare infrastructure.

The inactivated influenza vaccine market size is expected to see strong growth in the next few years. It will grow to$9.99 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to the rising demand for quadrivalent vaccines, the expansion of immunization programs, a growing focus on pandemic preparedness, technological advancements in vaccine production, and increasing global access to vaccines. Key trends during this period include a shift toward cell-based vaccine production, the growing adoption of adjuvanted formulations, the integration of influenza vaccines with COVID-19 boosters, rising demand in emerging markets, and the development of personalized vaccine strategies.

The growth of government vaccination programs is significantly boosting the inactivated influenza vaccine market. As public health awareness increases, governments are enhancing their immunization efforts, leading to greater demand for vaccines and more accessible immunization services. These programs play a critical role in providing free or subsidized inactivated influenza vaccines to high-risk groups, ensuring widespread vaccine coverage, and reducing the seasonal burden of influenza. For example, in December 2023, the UK's National Health Service (NHS) introduced a new vaccination strategy aimed at improving immunization outreach, particularly to underserved and marginalized communities. This strategy is designed to expand vaccination accessibility and further promote public health, which in turn is expected to drive growth in the inactivated influenza vaccine market.

Leading companies in the inactivated influenza vaccine market are increasingly focusing on the development of quadrivalent vaccines. These vaccines are designed to protect against four distinct strains of the influenza virus, offering broader protection and improving vaccine efficacy. For example, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, launched VaxiFlu-4, a quadrivalent inactivated influenza vaccine that provides protection against four strains of the flu virus. By covering both influenza A and B strains, this vaccine reduces the risk of vaccine mismatch and enhances protection against seasonal flu outbreaks, while also tailoring immune responses to regional epidemiological trends.

In July 2024, GSK plc, a UK-based pharmaceutical company, expanded its capabilities in mRNA vaccine development by acquiring the full rights to develop, manufacture, and commercialize mRNA-based influenza and COVID-19 vaccines from CureVac N.V. for an undisclosed amount. This acquisition allows GSK to leverage CureVac's advanced mRNA research to improve seasonal flu vaccines and boost pandemic preparedness strategies. CureVac, a Germany-based biotechnology company, specializes in mRNA-based therapeutics, including vaccines for influenza and cancer immunotherapy.

Major players in the inactivated influenza vaccine market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis International, GlaxoSmithKline plc, Viatris Inc., CSL, Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Dalian Aleph Biomedical Co. Ltd., Hualan Biological Bacterin Co. Ltd, Changchun Biological, Jiangsu gdk Biotechnology Co., Ltd., KM Biologics, JoinHub Pharma, and Pharmika India Private Limited.

North America was the largest region in the inactivated influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated influenza vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inactivated influenza vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inactivated influenza vaccine market consists of sales of adjuvanted inactivated influenza vaccines, preservative-free inactivated influenza vaccines, cell-based inactivated influenza vaccines, egg-based inactivated influenza vaccines, pediatric inactivated influenza vaccines, high-dose inactivated influenza vaccines for older adults, prefilled syringe vaccines, and multidose vial vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inactivated Influenza Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inactivated influenza vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inactivated influenza vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inactivated influenza vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Vaccine: Trivalent Inactivated Influenza Vaccine (TIIV); Quadrivalent Inactivated Influenza Vaccine (QIIV)
• 2) By Application: Children; Adolescence; Adults; Elderly
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Public Health Clinics
• 4) By End-User: Healthcare Providers; Individuals; Government Organizations; Pharmaceutical Companies
• Subsegments:
• 1) Trivalent Inactivated Influenza Vaccine (TIIV): Egg-based Trivalent Inactivated Influenza Vaccine; Cell-based Trivalent Inactivated Influenza Vaccine; Adjuvanted Trivalent Inactivated Influenza Vaccine; High-dose Trivalent Inactivated Influenza Vaccine
• 2) Quadrivalent Inactivated Influenza Vaccine (QIIV): Egg-based Quadrivalent Inactivated Influenza Vaccine; Cell-based Quadrivalent Inactivated Influenza Vaccine; Adjuvanted Quadrivalent Inactivated Influenza Vaccine; Recombinant Quadrivalent Inactivated Influenza Vaccine; Pediatric Quadrivalent Inactivated Influenza Vaccine
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Sanofi S.A.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inactivated Influenza Vaccine Market Characteristics

3. Inactivated Influenza Vaccine Market Trends And Strategies

4. Inactivated Influenza Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Inactivated Influenza Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Inactivated Influenza Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Inactivated Influenza Vaccine Market Growth Rate Analysis
• 5.4. Global Inactivated Influenza Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Inactivated Influenza Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Inactivated Influenza Vaccine Total Addressable Market (TAM)

6. Inactivated Influenza Vaccine Market Segmentation

• 6.1. Global Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trivalent Inactivated Influenza Vaccine (TIIV)
• Quadrivalent Inactivated Influenza Vaccine (QIIV)
• 6.2. Global Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Children
• Adolescence
• Adults
• Elderly
• 6.3. Global Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Public Health Clinics
• 6.4. Global Inactivated Influenza Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Healthcare Providers
• Individuals
• Government Organizations
• Pharmaceutical Companies
• 6.5. Global Inactivated Influenza Vaccine Market, Sub-Segmentation Of Trivalent Inactivated Influenza Vaccine (TIIV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Egg-based Trivalent Inactivated Influenza Vaccine
• Cell-based Trivalent Inactivated Influenza Vaccine
• Adjuvanted Trivalent Inactivated Influenza Vaccine
• High-dose Trivalent Inactivated Influenza Vaccine
• 6.6. Global Inactivated Influenza Vaccine Market, Sub-Segmentation Of Quadrivalent Inactivated Influenza Vaccine (QIIV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Egg-based Quadrivalent Inactivated Influenza Vaccine
• Cell-based Quadrivalent Inactivated Influenza Vaccine
• Adjuvanted Quadrivalent Inactivated Influenza Vaccine
• Recombinant Quadrivalent Inactivated Influenza Vaccine
• Pediatric Quadrivalent Inactivated Influenza Vaccine

7. Inactivated Influenza Vaccine Market Regional And Country Analysis

• 7.1. Global Inactivated Influenza Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Inactivated Influenza Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inactivated Influenza Vaccine Market

• 8.1. Asia-Pacific Inactivated Influenza Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inactivated Influenza Vaccine Market

• 9.1. China Inactivated Influenza Vaccine Market Overview
• 9.2. China Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inactivated Influenza Vaccine Market

• 10.1. India Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inactivated Influenza Vaccine Market

• 11.1. Japan Inactivated Influenza Vaccine Market Overview
• 11.2. Japan Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inactivated Influenza Vaccine Market

• 12.1. Australia Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inactivated Influenza Vaccine Market

• 13.1. Indonesia Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inactivated Influenza Vaccine Market

• 14.1. South Korea Inactivated Influenza Vaccine Market Overview
• 14.2. South Korea Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inactivated Influenza Vaccine Market

• 15.1. Western Europe Inactivated Influenza Vaccine Market Overview
• 15.2. Western Europe Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inactivated Influenza Vaccine Market

• 16.1. UK Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inactivated Influenza Vaccine Market

• 17.1. Germany Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inactivated Influenza Vaccine Market

• 18.1. France Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inactivated Influenza Vaccine Market

• 19.1. Italy Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inactivated Influenza Vaccine Market

• 20.1. Spain Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inactivated Influenza Vaccine Market

• 21.1. Eastern Europe Inactivated Influenza Vaccine Market Overview
• 21.2. Eastern Europe Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inactivated Influenza Vaccine Market

• 22.1. Russia Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inactivated Influenza Vaccine Market

• 23.1. North America Inactivated Influenza Vaccine Market Overview
• 23.2. North America Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inactivated Influenza Vaccine Market

• 24.1. USA Inactivated Influenza Vaccine Market Overview
• 24.2. USA Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inactivated Influenza Vaccine Market

• 25.1. Canada Inactivated Influenza Vaccine Market Overview
• 25.2. Canada Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inactivated Influenza Vaccine Market

• 26.1. South America Inactivated Influenza Vaccine Market Overview
• 26.2. South America Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inactivated Influenza Vaccine Market

• 27.1. Brazil Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inactivated Influenza Vaccine Market

• 28.1. Middle East Inactivated Influenza Vaccine Market Overview
• 28.2. Middle East Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inactivated Influenza Vaccine Market

• 29.1. Africa Inactivated Influenza Vaccine Market Overview
• 29.2. Africa Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inactivated Influenza Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Inactivated Influenza Vaccine Market Competitive Landscape
• 30.2. Inactivated Influenza Vaccine Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Inactivated Influenza Vaccine Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis International
• 31.3. GlaxoSmithKline plc
• 31.4. Viatris Inc.
• 31.5. CSL
• 31.6. Zydus Lifesciences Limited
• 31.7. Sinovac Biotech Ltd.
• 31.8. Bharat Biotech International Limited
• 31.9. Dalian Aleph Biomedical Co. Ltd.
• 31.10. Hualan Biological Bacterin Co. Ltd
• 31.11. Changchun Biological
• 31.12. Jiangsu gdk Biotechnology Co., Ltd.
• 31.13. KM Biologics
• 31.14. JoinHub Pharma
• 31.15. Pharmika India Private Limited

32. Global Inactivated Influenza Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inactivated Influenza Vaccine Market

34. Recent Developments In The Inactivated Influenza Vaccine Market

35. Inactivated Influenza Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Inactivated Influenza Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Inactivated Influenza Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Inactivated Influenza Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료